scholarly journals Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus

2009 ◽  
Vol 67 (5) ◽  
pp. 547-557 ◽  
Author(s):  
Nadia Rashid Al Mazroui ◽  
Mostafa Mohamed Kamal ◽  
Naserdeen Mehana Ghabash ◽  
Targ Ahmed Yacout ◽  
Prashant Laxman Kole ◽  
...  
2016 ◽  
Vol 11 (1) ◽  
pp. 93-94 ◽  
Author(s):  
Win Myat Maw ◽  
Mi Mi Saw ◽  
Theingi Kyaw ◽  
Khin Ohnmar Kyaing ◽  
Zaw Min Latt ◽  
...  

2011 ◽  
Vol 55 (9) ◽  
pp. 686-691 ◽  
Author(s):  
Anna Paula de Sá Borges ◽  
Camilo Molino Guidoni ◽  
Osvaldo de Freitas ◽  
Leonardo Régis Leira Pereira

OBJECTIVE: To analyze the costs related to visits and drug prescription in outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service. SUBJECTS AND METHODS: A prospective and experimental study was carried out. Seventy one patients were divided into two groups: control and pharmaceutical care. Patients in the pharmaceutical care group were followed up monthly by a single clinical pharmacist. RESULTS: The pharmaceutical care group had a statistically significant reduction in costs of metformin and emergency department visits, and increased costs with their family physicians. On the other hand, the control group had a statistically significant increase of 21.3% in the general costs of treatment and visits. CONCLUSION: The pharmaceutical care group maintained the same costs related to drugs and visits, while the control group showed a significant increase in general costs.


2016 ◽  
Vol 35 (3) ◽  
pp. 375-396 ◽  
Author(s):  
Michael Willis ◽  
Pierre Johansen ◽  
Andreas Nilsson ◽  
Christian Asseburg

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Inmaculada Guerrero Fernández de Alba ◽  
Antonio Gimeno-Miguel ◽  
Beatriz Poblador-Plou ◽  
Luis Andrés Gimeno-Feliu ◽  
Ignatios Ioakeim-Skoufa ◽  
...  

Abstract Type 2 diabetes mellitus (T2D) is often accompanied by chronic diseases, including mental health problems. We aimed at studying mental health comorbidity prevalence in T2D patients and its association with T2D outcomes through a retrospective, observational study of individuals of the EpiChron Cohort (Aragón, Spain) with prevalent T2D in 2011 (n = 63,365). Participants were categorized as having or not mental health comorbidity (i.e., depression, anxiety, schizophrenia, and/or substance use disorder). We performed logistic regression models, controlled for age, sex and comorbidities, to analyse the likelihood of 4-year mortality, 1-year all-cause hospitalization, T2D-hospitalization, and emergency room visit. Mental health comorbidity was observed in 19% of patients. Depression was the most frequent condition, especially in women (20.7% vs. 7.57%). Mortality risk was higher in patients with mental health comorbidity (odds ratio 1.24; 95% confidence interval 1.16–1.31), especially in those with substance use disorder (2.18; 1.84–2.57) and schizophrenia (1.82; 1.50–2.21). Mental health comorbidity also increased the likelihood of all-cause hospitalization (1.16; 1.10–1.23), T2D-hospitalization (1.51; 1.18–1.93) and emergency room visit (1.26; 1.21–1.32). These results suggest that T2D healthcare management should include specific strategies for the early detection and treatment of mental health problems to reduce its impact on health outcomes.


Sign in / Sign up

Export Citation Format

Share Document